Through our blog, we hope to create a community where we can support and challenge each other through conversations, discussions and storytelling, and work together to move the field of oncology forward.

  • Informing precision treatment approaches for breast cancer with FoundationACT liquid biopsy

    Breast cancer is an important example of how a better understanding of cancer biology can lead to more personalized and precise treatments that improve patient care and prognosis. Surgery, hormone therapy, and chemotherapy were the standard of care for decades, but research into the HER2 gene as a potential …

    Continue Reading

  • New Data Suggest Tumor Mutational Burden Could Help Predict Response to Immunotherapy Across an Array of Tumor Types

    Tumor mutational burden (TMB) is a genomic biomarker with the potential to make a significant impact on the landscape of cancer immunotherapy. This emerging marker measures the number of mutations within a tumor genome and has already been shown to be associated with improved responses to checkpoint inhibitor …

    Continue Reading

  • Expanding the Promise of Immunotherapy with Blood Tumor Mutational Burden (bTMB)

    A quick glance at the latest news coverage reveals the increasing pace of new treatment approvals and clinical advances in oncology, many of which are happening in one specific field: cancer immunotherapy. Some of these advances are being matched by new biomarkers to help predict who is most likely to benefit from …

    Continue Reading

  • Improving Clinical Trial Design with Tumor Mutational Burden

    Biomarkers are playing a transformative role in cancer drug development. Not only can they help identify patients most likely to respond to a medicine, they can also make a huge difference in drug development by improving outcomes in clinical trials. Just as the right biomarker can positively influence drug response …

    Continue Reading

  • Unleashing the Potential of Clinico-Genomic Information: ASCO 2017

    Precision oncology requires a robust understanding of how genomic information relates to clinical outcomes and treatment response. To make this connection, we need to integrate multiple sources of data into single databases that have the power to inform new clinical insights. This has historically been difficult …

    Continue Reading

  • Trials and Outcomes: Accelerating Precision Medicine at ASCO 2017

    At Foundation Medicine, our vision for precision oncology is based on fundamentally changing the way patients receive care. For us, this means enabling practical and clinically applicable solutions, no matter the stage or composition of the cancer, and regardless of where the patient lives or is being …

    Continue Reading

  • Evolving at the Speed of Cancer: FoundationACT® Liquid Biopsy Data at ASCO 2017

    Comprehensive genomic profiling has opened the door to more precise medicines for many patients. Researchers and oncologists can identify genomic drivers of cancer growth or resistance to therapy, often with just a small tissue sample. But even if a tissue biopsy isn’t feasible, such as in patients with advanced …

    Continue Reading

  • At ASCO 2017, Foundation Medicine is presenting new comprehensive genomic profiling data spanning 15 different tumor types. Learn more about the insights FoundationOne® can provide for both targeted therapies and immunotherapies across a range of different cancers. Learn more about our posters and presentations at …

    Continue Reading

  • This week was the American Association for Cancer Research (AACR) annual meeting in Washington, DC. As we followed the event, we identified the 140-character anecdotes and quotes that shine a light on emerging trends in cancer research. Cancer immunotherapy continues to be a hot topic. While the treatment landscape …

    Continue Reading